Increased α-synuclein phosphorylation and oligomerization and altered enzymes in plasma of patients with Parkinson’s disease

•PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of enzymes regulating α-syn phosphorylation is altered in PD plasma.•α-syn phosphorylation and oligomerization rates discriminate PD patients from...

Full description

Saved in:
Bibliographic Details
Published inNeuroscience Vol. 567; pp. 28 - 36
Main Authors Yin, Na, Li, Pengjie, Li, Xuran, Li, Xin, Wang, Yiming, Yu, Xiaohan, Deng, Yeyun, Wang, Chaodong, Yu, Shun
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 16.02.2025
Subjects
Online AccessGet full text
ISSN0306-4522
1873-7544
1873-7544
DOI10.1016/j.neuroscience.2024.12.056

Cover

Abstract •PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of enzymes regulating α-syn phosphorylation is altered in PD plasma.•α-syn phosphorylation and oligomerization rates discriminate PD patients from HCs. The brain of patients with Parkinson’s disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression.
AbstractList •PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of enzymes regulating α-syn phosphorylation is altered in PD plasma.•α-syn phosphorylation and oligomerization rates discriminate PD patients from HCs. The brain of patients with Parkinson’s disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression.
The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression.The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression.
The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered activity of enzymes regulating α-syn phosphorylation and oligomerization. Whether increased α-syn phosphorylation and oligomerization as well as related enzyme changes can be detected in the plasma of PD patients remains unclear. Here, we showed that human α-syn proteins incubated in PD plasma formed more oligomerized α-syn (O-α-syn) and phosphorylated α-syn (pS-α-syn) than those in healthy control (HC) plasma. Receiver operating characteristic (ROC) curve indicated that α-syn oligomerization rate and phosphorylation rate discriminated PD patients well from HC subjects. Moreover, they were both positively correlated with Hoehn and Yahr staging and polo-like kinase 2 (PLK2, an enzyme promoting α-syn phosphorylation) levels, and negatively correlated with protein phosphatase 2A levels (PP2A, an enzyme dephosphorylating α-syn) and glucocerebrosidase (GCase, an enzyme whose deficiency causes α-syn oligomerization) activity and ceramide (a product of GCase and a natural PP2A activator) levels. The above results suggest that increased α-syn oligomerization and phosphorylation rates and related enzyme changes can be detected in PD plasma and used to discriminate PD patients from HC subjects and predict PD progression.
Author Li, Pengjie
Yu, Xiaohan
Deng, Yeyun
Li, Xuran
Wang, Chaodong
Li, Xin
Yin, Na
Wang, Yiming
Yu, Shun
Author_xml – sequence: 1
  givenname: Na
  surname: Yin
  fullname: Yin, Na
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 2
  givenname: Pengjie
  surname: Li
  fullname: Li, Pengjie
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 3
  givenname: Xuran
  surname: Li
  fullname: Li, Xuran
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 4
  givenname: Xin
  surname: Li
  fullname: Li, Xin
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 5
  givenname: Yiming
  surname: Wang
  fullname: Wang, Yiming
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 6
  givenname: Xiaohan
  surname: Yu
  fullname: Yu, Xiaohan
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 7
  givenname: Yeyun
  surname: Deng
  fullname: Deng, Yeyun
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 8
  givenname: Chaodong
  surname: Wang
  fullname: Wang, Chaodong
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
– sequence: 9
  givenname: Shun
  surname: Yu
  fullname: Yu, Shun
  email: yushun103@163.com, yushun103@hotmail.com
  organization: Department of Neurobiology and National Clinical Research Center for Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39742943$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtu1TAUhi1URG8LW0AWIyYJfsR5MIPyqlQJBjC2HOeY-taxL3ZSlE5gGyyDjbAIVoKje3mIUS1Zlqzv_y2f7wQd-eABoUeUlJTQ-sm29DDHkLQFr6FkhFUlZSUR9R20oW3Di0ZU1RHaEE7qohKMHaOTlLYkL1Hxe-iYd03Fuopv0JdzryOoBAP-8b1Ii5-1A-vx7jKkvOPi1GSDx8oPODj7MYwQ7c3fO-UmiDkM_mYZIeE16lQaFQ4G7zIHfkr4s50u8TsVr6xPwf_8-i3hwab12fvorlEuwYPDeYo-vHr5_uxNcfH29fnZs4tC85ZNBa2NqHsziA4aCn1tmDbtoFTb1LzXBhhlLM-hh45rQuqh6qjhLSUd1UKBavgperzv3cXwaYY0ydEmDc4pD2FOklNBWi6adkUfHtC5H2GQu2hHFRf5e2gZeLoHdJaQIpg_CCVyNSS38l9DcjUkKZPZUA6_2Ich__baQpQHarAR9CSHYG9X8_y_Gu2st1q5K1huW_ILjEW8YA
Cites_doi 10.3390/ijms23116216
10.1111/jnc.14809
10.3390/cells8040364
10.3233/JPD-160779
10.1074/jbc.M208046200
10.3390/jcm8101601
10.1016/j.neuroscience.2015.05.035
10.1021/acschemneuro.8b00383
10.3390/ijms241310932
10.1016/j.neurobiolaging.2015.06.004
10.1016/S0140-6736(21)00218-X
10.1007/s11910-018-0860-4
10.1007/s00441-004-0956-9
10.3389/fnins.2018.00080
10.1038/emm.2001.39
10.1007/s00018-022-04240-2
10.1016/j.parkreldis.2022.06.001
10.3389/fgene.2014.00382
10.1074/jbc.274.29.20313
10.3390/ijms21228645
10.1016/j.parkreldis.2018.10.003
10.1074/jbc.C800206200
10.1016/j.nbd.2021.105291
10.1074/jbc.M600933200
10.3389/fnagi.2021.623977
10.2188/jea.12.280
10.1016/j.neuroscience.2013.09.061
10.1016/S0021-9258(18)82288-8
10.1038/s41593-019-0423-2
10.1007/s10072-020-04407-4
10.1042/bse0560125
10.1111/jnc.13234
10.1186/s40478-017-0452-6
10.1523/JNEUROSCI.6513-10.2011
10.1016/S0197-4580(02)00065-9
10.1038/cddis.2014.175
10.1016/j.neuroscience.2012.01.028
10.1002/mds.26424
10.1016/j.peptides.2014.09.018
10.1016/j.mcn.2018.12.005
10.1074/jbc.M109.081950
ContentType Journal Article
Copyright 2025 International Brain Research Organization (IBRO)
Copyright © 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2025 International Brain Research Organization (IBRO)
– notice: Copyright © 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.neuroscience.2024.12.056
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1873-7544
EndPage 36
ExternalDocumentID 39742943
10_1016_j_neuroscience_2024_12_056
S0306452224007632
Genre Journal Article
GroupedDBID ---
--K
--M
-DZ
-~X
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
5RE
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABCQJ
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABTEW
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGUBO
AGWIK
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
APXCP
AXJTR
BKOJK
BLXMC
CS3
DU5
EBS
EFJIC
EFKBS
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HMQ
IHE
J1W
KOM
L7B
M2V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OP~
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SSN
SSZ
T5K
UNMZH
Z5R
~G-
AFCTW
AGRNS
BNPGV
SSH
.55
.GJ
29N
53G
5VS
AAQXK
AAYXX
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
AGHFR
AGQPQ
AHHHB
ASPBG
AVWKF
AZFZN
CITATION
EJD
FEDTE
FGOYB
G-2
HVGLF
HZ~
R2-
RIG
SNS
WUQ
X7M
YYP
ZGI
ZXP
AACTN
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFLBG
ID FETCH-LOGICAL-c382t-16f56bfd59e71eb6f2cf8daa8763bcfe2122202be93c006d491f381091c5aea73
IEDL.DBID AIKHN
ISSN 0306-4522
1873-7544
IngestDate Thu Sep 04 23:54:28 EDT 2025
Thu May 01 02:19:42 EDT 2025
Tue Aug 05 12:08:54 EDT 2025
Sat Jun 28 18:17:05 EDT 2025
Tue Aug 26 20:14:02 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Phosphorylation
MoCA
H&Y stage
LRRK2
M-α-syn
pS-α-syn
AUC
SD
GRKs
L-DOPA
LEDD
α-synuclein
UPDRS III
O-α-syn
GCase
Oligomerization
Enzyme
PLK2
ROC
PP2A
LNs
SDS-PAGE
HAMD
PD
α-syn
GlcCer
HC
LBs
Parkinson’s disease
ELISA
Language English
License Copyright © 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c382t-16f56bfd59e71eb6f2cf8daa8763bcfe2122202be93c006d491f381091c5aea73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 39742943
PQID 3150835787
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_3150835787
pubmed_primary_39742943
crossref_primary_10_1016_j_neuroscience_2024_12_056
elsevier_sciencedirect_doi_10_1016_j_neuroscience_2024_12_056
elsevier_clinicalkey_doi_10_1016_j_neuroscience_2024_12_056
PublicationCentury 2000
PublicationDate 2025-02-16
PublicationDateYYYYMMDD 2025-02-16
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-16
  day: 16
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Neuroscience
PublicationTitleAlternate Neuroscience
PublicationYear 2025
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Sui, Bullock, Erickson, Zhang, Banks (b0170) 2014; 62
Zhang, Zhu, Sun, Zhi, Ding, Yuan (b0210) 2019; 60
Chalfant, Kishikawa, Mumby, Kamibayashi, Bielawska, Hannun (b0040) 1999; 274
Paul, Qureshi, Rana (b0145) 2020; 41
Chen, Yang, Li, Li, Yang, Xu, Yu (b0045) 2015; 300
Liu, Chen, Mi, Yang, Li, Wang (b0120) 2015; 36
Shahmoradian, Lewis, Genoud, Hench, Moors, Navarro (b0165) 2019; 22
Lee, Chen, Junn, Im, Grosso, Sonsalla (b0100) 2011; 31
Pérez-Revuelta, Hettich, Ciociaro, Rotermund, Kahle, Krauss, Di Monte (b0150) 2014; 5
Tofaris (b0180) 2022; 79
Oueslati (b0140) 2016; 6
Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The Role of α-Synuclein Oligomers in Parkinson's Disease.
Jiang, Tang, Meng, Futatsuka (b0090) 2002; 12
Arawaka, Sato, Sasaki, Koyama, Kato (b0010) 2017; 5
Postuma, Berg, Stern, Poewe, Olanow, Oertel (b0155) 2015; 30
8(4). doi: ARTN 36410.3390/cells8040364.
Taymans, Baekelandt (b0175) 2014; 5
Lin, C.H., Liu, H.C., Yang, S.Y., Yang, K.C., Wu, C.C., and Chiu, M.J. (2019). Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease.
8(10). doi: ARTN 160110.3390/jcm8101601.
Weston, Cook, Stackhouse, Sal, Schultz, Tobias (b0190) 2021; 152
Bergeron, Motter, Tanaka, Fauss, Babcock, Chiou (b0015) 2014; 256
Braak, Del Tredici, Rüb, de Vos, Jansen Steur, Braak (b0025) 2003; 24
Inglis, Chereau, Brigham, Chiou, Schöbel, Frigon (b0085) 2009; 284
Wu, Lou, Alerte, Stachowski, Chen, Singleton (b0195) 2012; 207
Dobrowsky, Kamibayashi, Mumby, Hannun (b0055) 1993; 268
Maass, Schulz, Lingor, Mollenhauer, Bähr (b0130) 2019; 97
Bloem, Okun, Klein (b0020) 2021; 397
Bridi, Hirth (b0035) 2018; 12
Li, Yuan, Li, Han, Liu, Yang (b0110) 2021; 2021
Riboldi, G.M., and Di Fonzo, A.B. (2019). GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.
Cocco, Manai, Manca, Noli (b0050) 2023; 24
21(22). doi: ARTN 864510.3390/ijms21228645.
Hasegawa, Fujiwara, Nonaka, Wakabayashi, Takahashi, Lee (b0080) 2002; 277
Anderson, Walker, Goldstein, de Laat, Banducci, Caccavello (b0005) 2006; 281
Mbefo, Paleologou, Boucharaba, Oueslati, Schell, Fournier (b0135) 2010; 285
Xu, Deng, Qing (b0200) 2015; 135
18(8). doi: ARTN 4410.1007/s11910-018-0860-4.
Wang, Li, Li, Yang, Yu (b0185) 2016; 2016
Ma, Liu, Wang, Zhang, Kou, Feng (b0125) 2019; 10
Yu, Chan (b0205) 2014; 56
Kawahata, Finkelstein, Fukunaga (b0095) 2022; 23
Fayyad, Salim, Majbour, Erskine, Stoops, Mollenhauer, El-Agnaf (b0065) 2019; 150
Zubelzu, Morera-Herreras, Irastorza, Gómez-Esteban, Murueta-Goyena (b0215) 2022; 99
Galadari, Hago, Patel (b0070) 2001; 33
Gan-Or, Z., Liong, C., and Alcalay, R.N. (2018). GBA-Associated Parkinson's Disease and Other Synucleinopathies.
Li, Li, Li, Li, Sun, Yang (b0105) 2021; 13
Braak, Ghebremedhin, Rüb, Bratzke, Del Tredici (b0030) 2004; 318
Weston (10.1016/j.neuroscience.2024.12.056_b0190) 2021; 152
Anderson (10.1016/j.neuroscience.2024.12.056_b0005) 2006; 281
Maass (10.1016/j.neuroscience.2024.12.056_b0130) 2019; 97
Oueslati (10.1016/j.neuroscience.2024.12.056_b0140) 2016; 6
Galadari (10.1016/j.neuroscience.2024.12.056_b0070) 2001; 33
Chen (10.1016/j.neuroscience.2024.12.056_b0045) 2015; 300
Sui (10.1016/j.neuroscience.2024.12.056_b0170) 2014; 62
Braak (10.1016/j.neuroscience.2024.12.056_b0025) 2003; 24
10.1016/j.neuroscience.2024.12.056_b0075
Tofaris (10.1016/j.neuroscience.2024.12.056_b0180) 2022; 79
Cocco (10.1016/j.neuroscience.2024.12.056_b0050) 2023; 24
Bergeron (10.1016/j.neuroscience.2024.12.056_b0015) 2014; 256
Dobrowsky (10.1016/j.neuroscience.2024.12.056_b0055) 1993; 268
Arawaka (10.1016/j.neuroscience.2024.12.056_b0010) 2017; 5
Ma (10.1016/j.neuroscience.2024.12.056_b0125) 2019; 10
Shahmoradian (10.1016/j.neuroscience.2024.12.056_b0165) 2019; 22
Wang (10.1016/j.neuroscience.2024.12.056_b0185) 2016; 2016
Chalfant (10.1016/j.neuroscience.2024.12.056_b0040) 1999; 274
10.1016/j.neuroscience.2024.12.056_b0115
Inglis (10.1016/j.neuroscience.2024.12.056_b0085) 2009; 284
Bridi (10.1016/j.neuroscience.2024.12.056_b0035) 2018; 12
Hasegawa (10.1016/j.neuroscience.2024.12.056_b0080) 2002; 277
Xu (10.1016/j.neuroscience.2024.12.056_b0200) 2015; 135
Mbefo (10.1016/j.neuroscience.2024.12.056_b0135) 2010; 285
Jiang (10.1016/j.neuroscience.2024.12.056_b0090) 2002; 12
Kawahata (10.1016/j.neuroscience.2024.12.056_b0095) 2022; 23
Liu (10.1016/j.neuroscience.2024.12.056_b0120) 2015; 36
Pérez-Revuelta (10.1016/j.neuroscience.2024.12.056_b0150) 2014; 5
Yu (10.1016/j.neuroscience.2024.12.056_b0205) 2014; 56
10.1016/j.neuroscience.2024.12.056_b0060
Paul (10.1016/j.neuroscience.2024.12.056_b0145) 2020; 41
10.1016/j.neuroscience.2024.12.056_b0160
Taymans (10.1016/j.neuroscience.2024.12.056_b0175) 2014; 5
Zubelzu (10.1016/j.neuroscience.2024.12.056_b0215) 2022; 99
Postuma (10.1016/j.neuroscience.2024.12.056_b0155) 2015; 30
Wu (10.1016/j.neuroscience.2024.12.056_b0195) 2012; 207
Fayyad (10.1016/j.neuroscience.2024.12.056_b0065) 2019; 150
Li (10.1016/j.neuroscience.2024.12.056_b0110) 2021; 2021
Li (10.1016/j.neuroscience.2024.12.056_b0105) 2021; 13
Braak (10.1016/j.neuroscience.2024.12.056_b0030) 2004; 318
Bloem (10.1016/j.neuroscience.2024.12.056_b0020) 2021; 397
Zhang (10.1016/j.neuroscience.2024.12.056_b0210) 2019; 60
Lee (10.1016/j.neuroscience.2024.12.056_b0100) 2011; 31
References_xml – reference: . 21(22). doi: ARTN 864510.3390/ijms21228645.
– volume: 12
  start-page: 280
  year: 2002
  end-page: 286
  ident: b0090
  article-title: Demographic determinants for change in activities of daily living: a cohort study of the elderly people in Beijing
– volume: 30
  start-page: 1591
  year: 2015
  end-page: 1601
  ident: b0155
  article-title: MDS clinical diagnostic criteria for Parkinson's disease
– volume: 5
  start-page: 382
  year: 2014
  ident: b0175
  article-title: Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
– volume: 60
  start-page: 57
  year: 2019
  end-page: 63
  ident: b0210
  article-title: Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease
– volume: 99
  start-page: 107
  year: 2022
  end-page: 115
  ident: b0215
  article-title: Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis
  publication-title: .
– volume: 150
  start-page: 626
  year: 2019
  end-page: 636
  ident: b0065
  article-title: Parkinson's disease biomarkers based on α-synuclein
– volume: 277
  start-page: 49071
  year: 2002
  end-page: 49076
  ident: b0080
  article-title: Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions
– volume: 24
  year: 2023
  ident: b0050
  article-title: Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease
– reference: 8(10). doi: ARTN 160110.3390/jcm8101601.
– volume: 10
  start-page: 812
  year: 2019
  end-page: 823
  ident: b0125
  article-title: Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease
– volume: 300
  start-page: 297
  year: 2015
  end-page: 306
  ident: b0045
  article-title: α-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation
– reference: 18(8). doi: ARTN 4410.1007/s11910-018-0860-4.
– volume: 22
  year: 2019
  ident: b0165
  article-title: Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes
– reference: Lin, C.H., Liu, H.C., Yang, S.Y., Yang, K.C., Wu, C.C., and Chiu, M.J. (2019). Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease.
– volume: 56
  start-page: 125
  year: 2014
  end-page: 135
  ident: b0205
  article-title: Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease
– volume: 281
  start-page: 29739
  year: 2006
  end-page: 29752
  ident: b0005
  article-title: Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease
– volume: 36
  start-page: 2649
  year: 2015
  end-page: 2659
  ident: b0120
  article-title: Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains
– volume: 23
  year: 2022
  ident: b0095
  article-title: Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
– volume: 97
  start-page: 60
  year: 2019
  end-page: 66
  ident: b0130
  article-title: Cerebrospinal fluid biomarker for Parkinson's disease: An overview
– reference: 8(4). doi: ARTN 36410.3390/cells8040364.
– reference: Riboldi, G.M., and Di Fonzo, A.B. (2019). GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.
– volume: 135
  start-page: 4
  year: 2015
  end-page: 18
  ident: b0200
  article-title: The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease
– volume: 41
  start-page: 2691
  year: 2020
  end-page: 2701
  ident: b0145
  article-title: Peripheral neuropathy in Parkinson's disease
– volume: 256
  start-page: 72
  year: 2014
  end-page: 82
  ident: b0015
  article-title: In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain
– volume: 6
  start-page: 39
  year: 2016
  end-page: 51
  ident: b0140
  article-title: Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
– volume: 268
  start-page: 15523
  year: 1993
  end-page: 15530
  ident: b0055
  article-title: Ceramide activates heterotrimeric protein phosphatase 2A
– volume: 318
  start-page: 121
  year: 2004
  end-page: 134
  ident: b0030
  article-title: Stages in the development of Parkinson's disease-related pathology
– volume: 62
  start-page: 197
  year: 2014
  end-page: 202
  ident: b0170
  article-title: Alpha synuclein is transported into and out of the brain by the blood-brain barrier
– volume: 397
  start-page: 2284
  year: 2021
  end-page: 2303
  ident: b0020
  article-title: Parkinson's disease
– volume: 31
  start-page: 6963
  year: 2011
  end-page: 6971
  ident: b0100
  article-title: Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model
– volume: 2021
  year: 2021
  ident: b0110
  article-title: Inhibition of α-Synuclein Accumulation Improves Neuronal Apoptosis and Delayed Postoperative Cognitive Recovery in Aged Mice
– reference: Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The Role of α-Synuclein Oligomers in Parkinson's Disease.
– volume: 13
  year: 2021
  ident: b0105
  article-title: Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease
– volume: 2016
  year: 2016
  ident: b0185
  article-title: Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity
– volume: 284
  start-page: 2598
  year: 2009
  end-page: 2602
  ident: b0085
  article-title: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system
– volume: 79
  start-page: 210
  year: 2022
  ident: b0180
  article-title: Initiation and progression of α-synuclein pathology in Parkinson's disease
– volume: 12
  year: 2018
  ident: b0035
  article-title: Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
– volume: 274
  start-page: 20313
  year: 1999
  end-page: 20317
  ident: b0040
  article-title: Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid
– volume: 285
  start-page: 2807
  year: 2010
  end-page: 2822
  ident: b0135
  article-title: Phosphorylation of Synucleins by Members of the Polo-like Kinase Family
– volume: 152
  year: 2021
  ident: b0190
  article-title: In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129
  publication-title: .
– volume: 33
  start-page: 240
  year: 2001
  end-page: 244
  ident: b0070
  article-title: Effects of cations on ceramide-activated protein phosphatase 2A
– volume: 5
  year: 2014
  ident: b0150
  article-title: Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation
– reference: Gan-Or, Z., Liong, C., and Alcalay, R.N. (2018). GBA-Associated Parkinson's Disease and Other Synucleinopathies.
– volume: 5
  year: 2017
  ident: b0010
  article-title: Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates
– volume: 24
  start-page: 197
  year: 2003
  end-page: 211
  ident: b0025
  article-title: Staging of brain pathology related to sporadic Parkinson's disease
– volume: 207
  start-page: 288
  year: 2012
  end-page: 297
  ident: b0195
  article-title: Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo
– volume: 23
  issue: 11
  year: 2022
  ident: 10.1016/j.neuroscience.2024.12.056_b0095
  article-title: Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23116216
– volume: 150
  start-page: 626
  issue: 5
  year: 2019
  ident: 10.1016/j.neuroscience.2024.12.056_b0065
  article-title: Parkinson's disease biomarkers based on α-synuclein
  publication-title: J. Neurochem.
  doi: 10.1111/jnc.14809
– ident: 10.1016/j.neuroscience.2024.12.056_b0160
  doi: 10.3390/cells8040364
– volume: 6
  start-page: 39
  issue: 1
  year: 2016
  ident: 10.1016/j.neuroscience.2024.12.056_b0140
  article-title: Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
  publication-title: J. Parkinsons Dis.
  doi: 10.3233/JPD-160779
– volume: 277
  start-page: 49071
  issue: 50
  year: 2002
  ident: 10.1016/j.neuroscience.2024.12.056_b0080
  article-title: Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M208046200
– ident: 10.1016/j.neuroscience.2024.12.056_b0115
  doi: 10.3390/jcm8101601
– volume: 2016
  year: 2016
  ident: 10.1016/j.neuroscience.2024.12.056_b0185
  article-title: Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity
  publication-title: Parkinsons Dis.
– volume: 300
  start-page: 297
  year: 2015
  ident: 10.1016/j.neuroscience.2024.12.056_b0045
  article-title: α-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2015.05.035
– volume: 10
  start-page: 812
  issue: 2
  year: 2019
  ident: 10.1016/j.neuroscience.2024.12.056_b0125
  article-title: Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.8b00383
– volume: 24
  issue: 13
  year: 2023
  ident: 10.1016/j.neuroscience.2024.12.056_b0050
  article-title: Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms241310932
– volume: 36
  start-page: 2649
  issue: 9
  year: 2015
  ident: 10.1016/j.neuroscience.2024.12.056_b0120
  article-title: Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains
  publication-title: Neurobiol. Aging
  doi: 10.1016/j.neurobiolaging.2015.06.004
– volume: 397
  start-page: 2284
  issue: 10291
  year: 2021
  ident: 10.1016/j.neuroscience.2024.12.056_b0020
  article-title: Parkinson's disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00218-X
– ident: 10.1016/j.neuroscience.2024.12.056_b0075
  doi: 10.1007/s11910-018-0860-4
– volume: 318
  start-page: 121
  issue: 1
  year: 2004
  ident: 10.1016/j.neuroscience.2024.12.056_b0030
  article-title: Stages in the development of Parkinson's disease-related pathology
  publication-title: Cell Tissue Res.
  doi: 10.1007/s00441-004-0956-9
– volume: 12
  year: 2018
  ident: 10.1016/j.neuroscience.2024.12.056_b0035
  article-title: Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
  publication-title: Front. Neurosci.
  doi: 10.3389/fnins.2018.00080
– volume: 33
  start-page: 240
  issue: 4
  year: 2001
  ident: 10.1016/j.neuroscience.2024.12.056_b0070
  article-title: Effects of cations on ceramide-activated protein phosphatase 2A
  publication-title: Exp. Mo.l Med.
  doi: 10.1038/emm.2001.39
– volume: 79
  start-page: 210
  issue: 4
  year: 2022
  ident: 10.1016/j.neuroscience.2024.12.056_b0180
  article-title: Initiation and progression of α-synuclein pathology in Parkinson's disease
  publication-title: Cell Mol. Life Sci.
  doi: 10.1007/s00018-022-04240-2
– volume: 99
  start-page: 107
  year: 2022
  ident: 10.1016/j.neuroscience.2024.12.056_b0215
  article-title: Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis
  publication-title: Parkinsonism Relat. Disord.
  doi: 10.1016/j.parkreldis.2022.06.001
– volume: 5
  start-page: 382
  year: 2014
  ident: 10.1016/j.neuroscience.2024.12.056_b0175
  article-title: Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2014.00382
– volume: 274
  start-page: 20313
  issue: 29
  year: 1999
  ident: 10.1016/j.neuroscience.2024.12.056_b0040
  article-title: Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.274.29.20313
– ident: 10.1016/j.neuroscience.2024.12.056_b0060
  doi: 10.3390/ijms21228645
– volume: 60
  start-page: 57
  year: 2019
  ident: 10.1016/j.neuroscience.2024.12.056_b0210
  article-title: Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease
  publication-title: Parkinsonism Relat. Disord.
  doi: 10.1016/j.parkreldis.2018.10.003
– volume: 284
  start-page: 2598
  issue: 5
  year: 2009
  ident: 10.1016/j.neuroscience.2024.12.056_b0085
  article-title: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.C800206200
– volume: 152
  year: 2021
  ident: 10.1016/j.neuroscience.2024.12.056_b0190
  article-title: In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129
  publication-title: Neurobiol. Dis.
  doi: 10.1016/j.nbd.2021.105291
– volume: 281
  start-page: 29739
  issue: 40
  year: 2006
  ident: 10.1016/j.neuroscience.2024.12.056_b0005
  article-title: Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M600933200
– volume: 13
  year: 2021
  ident: 10.1016/j.neuroscience.2024.12.056_b0105
  article-title: Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2021.623977
– volume: 12
  start-page: 280
  issue: 3
  year: 2002
  ident: 10.1016/j.neuroscience.2024.12.056_b0090
  article-title: Demographic determinants for change in activities of daily living: a cohort study of the elderly people in Beijing
  publication-title: J. Epidemiol.
  doi: 10.2188/jea.12.280
– volume: 2021
  year: 2021
  ident: 10.1016/j.neuroscience.2024.12.056_b0110
  article-title: Inhibition of α-Synuclein Accumulation Improves Neuronal Apoptosis and Delayed Postoperative Cognitive Recovery in Aged Mice
  publication-title: Oxid. Med. Cell Longev.
– volume: 256
  start-page: 72
  year: 2014
  ident: 10.1016/j.neuroscience.2024.12.056_b0015
  article-title: In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2013.09.061
– volume: 268
  start-page: 15523
  issue: 21
  year: 1993
  ident: 10.1016/j.neuroscience.2024.12.056_b0055
  article-title: Ceramide activates heterotrimeric protein phosphatase 2A
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(18)82288-8
– volume: 22
  issue: 7
  year: 2019
  ident: 10.1016/j.neuroscience.2024.12.056_b0165
  article-title: Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes
  publication-title: Nat. Neurosci.
  doi: 10.1038/s41593-019-0423-2
– volume: 41
  start-page: 2691
  issue: 10
  year: 2020
  ident: 10.1016/j.neuroscience.2024.12.056_b0145
  article-title: Peripheral neuropathy in Parkinson's disease
  publication-title: Neurol. Sci.
  doi: 10.1007/s10072-020-04407-4
– volume: 56
  start-page: 125
  year: 2014
  ident: 10.1016/j.neuroscience.2024.12.056_b0205
  article-title: Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease
  publication-title: Essays Biochem.
  doi: 10.1042/bse0560125
– volume: 135
  start-page: 4
  issue: 1
  year: 2015
  ident: 10.1016/j.neuroscience.2024.12.056_b0200
  article-title: The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease
  publication-title: J. Neurochem.
  doi: 10.1111/jnc.13234
– volume: 5
  year: 2017
  ident: 10.1016/j.neuroscience.2024.12.056_b0010
  article-title: Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates
  publication-title: Acta. Neuropathol. Commun.
  doi: 10.1186/s40478-017-0452-6
– volume: 31
  start-page: 6963
  issue: 19
  year: 2011
  ident: 10.1016/j.neuroscience.2024.12.056_b0100
  article-title: Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.6513-10.2011
– volume: 24
  start-page: 197
  issue: 2
  year: 2003
  ident: 10.1016/j.neuroscience.2024.12.056_b0025
  article-title: Staging of brain pathology related to sporadic Parkinson's disease
  publication-title: Neurobiol. Aging
  doi: 10.1016/S0197-4580(02)00065-9
– volume: 5
  year: 2014
  ident: 10.1016/j.neuroscience.2024.12.056_b0150
  article-title: Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2014.175
– volume: 207
  start-page: 288
  year: 2012
  ident: 10.1016/j.neuroscience.2024.12.056_b0195
  article-title: Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2012.01.028
– volume: 30
  start-page: 1591
  issue: 12
  year: 2015
  ident: 10.1016/j.neuroscience.2024.12.056_b0155
  article-title: MDS clinical diagnostic criteria for Parkinson's disease
  publication-title: Mov. Disord.
  doi: 10.1002/mds.26424
– volume: 62
  start-page: 197
  year: 2014
  ident: 10.1016/j.neuroscience.2024.12.056_b0170
  article-title: Alpha synuclein is transported into and out of the brain by the blood-brain barrier
  publication-title: Peptides
  doi: 10.1016/j.peptides.2014.09.018
– volume: 97
  start-page: 60
  year: 2019
  ident: 10.1016/j.neuroscience.2024.12.056_b0130
  article-title: Cerebrospinal fluid biomarker for Parkinson's disease: An overview
  publication-title: Mol. Cell Neurosci.
  doi: 10.1016/j.mcn.2018.12.005
– volume: 285
  start-page: 2807
  issue: 4
  year: 2010
  ident: 10.1016/j.neuroscience.2024.12.056_b0135
  article-title: Phosphorylation of Synucleins by Members of the Polo-like Kinase Family
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.081950
SSID ssj0000543
Score 2.4671652
Snippet •PD plasma promotes α-syn phosphorylation and oligomerization.•α-syn phosphorylation and oligomerization rates are higher in PD than in HC plasma.•Levels of...
The brain of patients with Parkinson's disease (PD) was characterized by increased phosphorylation and oligomerization of α-synuclein (α-syn) and altered...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 28
SubjectTerms Aged
alpha-Synuclein - blood
alpha-Synuclein - metabolism
Ceramides - blood
Enzyme
Female
Glucosylceramidase - blood
Humans
Male
Middle Aged
Oligomerization
Parkinson Disease - blood
Parkinson Disease - enzymology
Parkinson’s disease
Phosphorylation
Protein Phosphatase 2 - blood
Protein Serine-Threonine Kinases - blood
Protein Serine-Threonine Kinases - metabolism
α-synuclein
Title Increased α-synuclein phosphorylation and oligomerization and altered enzymes in plasma of patients with Parkinson’s disease
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0306452224007632
https://dx.doi.org/10.1016/j.neuroscience.2024.12.056
https://www.ncbi.nlm.nih.gov/pubmed/39742943
https://www.proquest.com/docview/3150835787
Volume 567
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELbK9sIFAeVnC1RGQtzMbmzHG6vqYVW1WqjaC1TqzUpiG7bqOqtme9geoK_BY_AifQiepDNO0h-pSJU45GJllMRjz0w833xDyAer4I_aqiFzhbdMpqJk4PQk467IJOfFyMYeS_sHanIovxylRytku6uFQVhla_sbmx6tdTsyaGdzMJ9OB18x2kU-cERBwi4BO7zKhVZpj6yOP-9NDm4MctqA5-B-hgId92iEed2ijUTWTC7j6SD2s77fT_0rDo3-aPcpedIGknTcvOszsuLCc7I2DvATPVvSjzRCO-OZ-Rr5BVYAwefO0ss_rF4GJDGeBjr_UdVwnS4bQBzNg6XVyfR7hWmc85uxmFIHYRfOlzNXUxSFqHuW08rTlpm1pnikS7GKOhaU_b34XdM2_fOCHO7ufNuesLbzAitFxhcsUT5VoLxUu1HiCuV56TOb50hfV5Tegb_jMFeF06KEbWulTjxShemkTHOXj8RL0gtVcK8Jtc7pofWp0FZJK7wuJXKPDjOrrcy46xPRzbOZNwQbpkOeHZvb2jGoHZNwA9rpk81OJaYrIQWjZ8APPEh661r6zmJ7sPz7bhUY2I2YYsmDq85qIyK9PlrBPnnVLI_rr4LID5y_FOv_-fQ35DHHJsTYlUa9Jb3F6Zl7B5HRotggjz79TDba9X8F4fsUoQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELaqcqCXCligCxRcCXELu7GdbCLUQ1VRLfTnQiv1ZiXxuN2q66ya7WF7AF6Dx-BF-hB9EmacZHeRqFSJQy5WRk489szY8_kbxt6bGHfUJu4HkFsTqEgWATo9FQjIEyVEPjC-xtLhUTw8UV9Po9MVttvehSFYZWP7a5vurXXT0mtGszcZjXrfKNolPnBCQeIqQTv8CPsaEK7v4_cFzgNjkrpGMm6d6fWWedSDvJZII4kzUyh_NkjVrP_tpe6LQr032nvC1pswku_UX_qUrYB7xjo7DrfQ4xn_wD2w05-Yd9gPtAEEPQfDb38H1cwRhfHI8cl5WeFzNavhcDxzhpeXo7OSkjg3izafUEdhcDezMVScRDHmHme8tLzhZa04HehyukPtr5Pd_fxV8Sb585yd7H0-3h0GTd2FoJCJmAZhbKMYVRelMAghj60obGKyjMjr8sICejuBY5VDKgtctEaloSWisDQsogyygXzBVl3pYINxA5D2jY1kamJlpE0LRcyj_cSkRiUCuky246wnNb2GbnFnF3pZO5q0o0OhUTtd9qlViW4vkKLJ0-gFHiS9PZf-a6o9WH6rnQUa1yIlWDIH5XWlpSfXJxvYZS_r6TH_K4z70PUr-eo_e3_HHg-PDw_0wZej_ddsTVA5YqpPE79hq9Ora9jEGGmav_Vr4A9J6RVs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+%CE%B1-synuclein+phosphorylation+and+oligomerization+and+altered+enzymes+in+plasma+of+patients+with+Parkinson%27s+disease&rft.jtitle=Neuroscience&rft.au=Yin%2C+Na&rft.au=Li%2C+Pengjie&rft.au=Li%2C+Xuran&rft.au=Li%2C+Xin&rft.date=2025-02-16&rft.eissn=1873-7544&rft.volume=567&rft.spage=28&rft_id=info:doi/10.1016%2Fj.neuroscience.2024.12.056&rft_id=info%3Apmid%2F39742943&rft.externalDocID=39742943
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-4522&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-4522&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-4522&client=summon